Literature DB >> 11031211

Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position.

G Subbanagounder1, N Leitinger, D C Schwenke, J W Wong, H Lee, C Rizza, A D Watson, K F Faull, A M Fogelman, J A Berliner.   

Abstract

We previously described 3 bioactive oxidation products of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (PAPC) containing oxovaleroyl (POVPC), glutaroyl (PGPC), and epoxyisoprostane (PEIPC) groups at the sn-2 position that were increased in minimally modified/oxidized low density lipoprotein (MM-LDL) and rabbit atherosclerotic lesions. We demonstrated specific and contrasting effects of POVPC and PGPC on leukocyte-endothelial interactions and described an effect of PEIPC on monocyte binding. The major purpose of the present study was to determine the effects of structural changes on the bioactivities of these 3 lipids. We demonstrate herein that the group at the sn-2 position determines the specific bioactivity and that the substitution of stearoyl for palmitoyl at the sn-1 position or ethanolamine for choline at the sn-3 position of the phospholipid did not alter bioactivity. Oxidized PAPC, oxidized 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine, and oxidized 1-stearoyl-2-arachidonoyl-sn-glycero-3-phosphorylethanolamine stimulated monocyte binding and inhibited lipopolysaccharide-induced expression of the neutrophil-binding molecule E-selectin. Furthermore, all oxovaleroyl phospholipids but not the glutaroyl phospholipids induced monocyte binding without an increase in vascular cell adhesion molecule-1 (VCAM-1) expression and inhibited lipopolysaccharide-induced E-selectin expression. In contrast, glutaroyl phospholipids but not oxovaleroyl phospholipids stimulated E-selectin and VCAM-1 expression. We further demonstrate that all parts of the phospholipid molecules are required for these bioactivities. Hydrolysis with phospholipase (PL) A(1), PLA(2), and PLC strongly reduced the bioactivities of POVPC, PGPC, and mixed isomers of PEIPC. PLD had a smaller but still significant effect. The effects of POVPC and PEIPC could be abolished by sodium borohydride treatment, indicating the importance of the reducible groups (carbonyl and epoxide) in these molecules. In summary, these studies identify 6 new bioactive, oxidized phospholipids that are increased in MM-LDL and, where measured, in atherosclerotic lesions. They thus suggest that a family of phospholipid oxidation products containing oxovaleroyl, glutaroyl, and epoxyisoprostane at the sn-2 position play an important role in the regulation of leukocyte-endothelial interactions, bioactivity being in part controlled by several types of phospholipid hydrolases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11031211     DOI: 10.1161/01.atv.20.10.2248

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  74 in total

1.  Reductive metabolism increases the proinflammatory activity of aldehyde phospholipids.

Authors:  Elena Vladykovskaya; Evgeny Ozhegov; J David Hoetker; Zhengzhi Xie; Yonis Ahmed; Jill Suttles; Sanjay Srivastava; Aruni Bhatnagar; Oleg A Barski
Journal:  J Lipid Res       Date:  2011-09-27       Impact factor: 5.922

2.  Gene expression analyses of mouse aortic endothelium in response to atherogenic stimuli.

Authors:  Ayca Erbilgin; Nathan Siemers; Paul Kayne; Wen-pin Yang; Judith Berliner; Aldons J Lusis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-29       Impact factor: 8.311

Review 3.  Anti-inflammatory properties of HDL.

Authors:  Benjamin J Ansell; Mohamad Navab; Karol E Watson; Gregg C Fonarow; Alan M Fogelman
Journal:  Rev Endocr Metab Disord       Date:  2004-12       Impact factor: 6.514

4.  A role for NADPH oxidase 4 in the activation of vascular endothelial cells by oxidized phospholipids.

Authors:  Sangderk Lee; Nima M Gharavi; Henry Honda; Irene Chang; Brandon Kim; Nelson Jen; Rongsong Li; Alejandro Zimman; Judith A Berliner
Journal:  Free Radic Biol Med       Date:  2009-04-16       Impact factor: 7.376

Review 5.  The aldo-keto reductase superfamily and its role in drug metabolism and detoxification.

Authors:  Oleg A Barski; Srinivas M Tipparaju; Aruni Bhatnagar
Journal:  Drug Metab Rev       Date:  2008       Impact factor: 4.518

6.  Structural basis for the recognition of oxidized phospholipids in oxidized low density lipoproteins by class B scavenger receptors CD36 and SR-BI.

Authors:  Detao Gao; Mohammad Z Ashraf; Niladri S Kar; De Lin; Lawrence M Sayre; Eugene A Podrez
Journal:  J Biol Chem       Date:  2009-12-08       Impact factor: 5.157

7.  Depletion of Bcl-2 by an antisense oligonucleotide induces apoptosis accompanied by oxidation and externalization of phosphatidylserine in NCI-H226 lung carcinoma cells.

Authors:  Patrick P Koty; Yulia Y Tyurina; Vladimir A Tyurin; Shang-Xi Li; Valerian E Kagan
Journal:  Mol Cell Biochem       Date:  2002 May-Jun       Impact factor: 3.396

8.  Fatty acid epoxyisoprostane E2 stimulates an oxidative stress response in endothelial cells.

Authors:  Xinmin Yan; Sangderk Lee; B Gabriel Gugiu; Lukasz Koroniak; Michael E Jung; Judith Berliner; Jinluo Cheng; Rongsong Li
Journal:  Biochem Biophys Res Commun       Date:  2014-01-14       Impact factor: 3.575

9.  ATF4-dependent transcription is a key mechanism in VEGF up-regulation by oxidized phospholipids: critical role of oxidized sn-2 residues in activation of unfolded protein response.

Authors:  Olga V Oskolkova; Taras Afonyushkin; Alexander Leitner; Elena von Schlieffen; Peter S Gargalovic; Aldons J Lusis; Bernd R Binder; Valery N Bochkov
Journal:  Blood       Date:  2008-05-01       Impact factor: 22.113

10.  Phospholipid-esterified eicosanoids are generated in agonist-activated human platelets and enhance tissue factor-dependent thrombin generation.

Authors:  Christopher P Thomas; Lloyd T Morgan; Benjamin H Maskrey; Robert C Murphy; Hartmut Kühn; Stanley L Hazen; Alison H Goodall; Hassan A Hamali; Peter W Collins; Valerie B O'Donnell
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.